RecruitingNCT03192501
iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray
Multicentre Perspective Non-interventional Study of Survival Benefits of iCAGES-guided Therapy in Contrast to Standard Therapy or IHC-guided Therapy for Advanced Cancers
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Enrollment
250 participants
Start Date
Jul 1, 2017
Study Type
OBSERVATIONAL
Conditions
Summary
This study prospectively evaluates whether the use of iCAGES (integrated CAncer GEnome Score) tool in guiding the treatment of advanced cancers is superior to current standard care or IHC-guided therapy in progress free survival (PFS),overall survival (OS),and improvement of life quality.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria3
- Pathological and clinical diagnosis of recurrence / metastatic lung cancer or other advanced cancers.
- There are PACS images available at the Second Affiliated Hospital of Guangzhou Medical University and the collaborated Hospitals.
- The patient is informed consent and signed a written consent.
Exclusion Criteria4
- Age \> 70 or \<18 years old.
- Previous history of malignant tumors.
- Pregnant or lactating female patients.
- Any serious concomitant disease that is expected to have an adverse effect on prognosis, including the heart disease that treatment is required, unsatisfactory controlled diabetes and psychiatric disorders.
Interventions
DRUGinhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.
Choose appropriate targeted drugs according to NGS/IHC results.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03192501
Related Trials
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
Virtual Agent Feasibility in Oncology Patients (NTT Data)
NCT066820131 location
Empathic Communication Skills (ECS) Training
NCT0545684112 locations
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Lung Cancer Screening in HIgh Risk nonsmokErs by Artificial inteLligence Device
NCT062954971 location